INDIANAPOLIS, Oct. 1, 2010 (GLOBE NEWSWIRE) -- Positron Corporation (OTCBB:POSC), a leading molecular imaging company specializing in the field of nuclear cardiology, is pleased to report its attendance at the American Society of Nuclear Cardiology (ASNC) annual meeting was met with great enthusiasm and interest. The conference took place in Philadelphia, PA, September 23-26, where Positron held a special cardiac PET symposium featuring K. Lance Gould M.D. as keynote speaker.
The ASNC is a well-known, leading source of information in the nuclear cardiology community. This year's annual meeting presented an abundance of data and research pertaining to cardiac PET applications, more so than any other prior forum. Of particular focus at the conference was the move from qualitative to quantitative imaging by measuring absolute coronary flow reserve (CFR). As a pioneer in the field of cardiac PET, the Positron symposium was a well-attended event. Dr. K. Lance Gould, from the University of Texas, presented to a standing-room only crowd his life's work on CFR.
"We were thrilled by the overwhelming response and interest in our technology, which only serves to reinforce and validate the strong commitment we've made to developing industry leading, cardiac-specific PET technology. We were honored to have Dr. Gould present on our behalf, as his passion and experience in the field is simply unrivaled.
"We are confident that Positron's Attrius is the ideal PET scanner for physician groups and hospitals looking to enter into cardiac PET imaging, and expect our sales growth will be reflective of that in both the coming quarters and over the long-term," Joseph Oliverio, CTO of Positron stated.
Traffic at Positron's display booth was at an all-time high at this year's conference, giving further credence to the industry acceptance and validity of its business strategy in introducing cost-effective dedicated PET optimized for cardiovascular imaging. Positron has remained focused on cardiac imaging and believes that significant investments made in both time and capital are paying off. Positron currently has intellectual property exclusivity rights with the University of Texas where Dr. Gould has completed and transferred his CFR software for Positron to immediately commercialize for future release.
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius(TM), a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the Tech-Assist(TM), a radiopharmaceutical injection shield. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.